Back to search results

Magnetic Resonance Spectroscopy (MRS) Scan for Spinal Cord Lesions

This study is exploring if a Magnetic Resonance Spectroscopy (MRS) Scan, a special type of MRI, can help doctors understand spinal cord lesions. The study aims to see if MRS can effectively assess these lesions and map the entire spine. Researchers will also test the MRS protocol on a small group of patients with low volume leptomeningeal disease (LMD), a type of cancer that spreads to the membranes around the brain and spinal cord, who are receiving radiation therapy. This will help them understand how radiation affects the spinal cord over time. The study is currently unclear on its recruitment status and plans to enroll 13 participants. The main goal is to check the safety of the MRS scan and any side effects.

Study design
This is an interventional study with an unclear phase, planning to enroll 13 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will receive a Magnetic Resonance Spectroscopy (MRS) Scan. Safety and side effects will be monitored through study completion, which is an average of 1 year.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and adverse events through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06548776

Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord

Recruiting
NAAges 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~13 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:Magnetic Resonance Spectroscopy (MRS) Scan

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year.

Conditions

Spinal Cord

Explore related trials

HealthyLeptomeningeal Disease

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Rami Eldaya, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Rami Eldaya, MD
[email protected]
(713) 745-2945
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults \> 18 years
Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions.
Consent able patients.
Adults \> 18 years old.
MR or CSF with evidence of LMD.
Patients to receive CSI as part of standard treatment of LMD disease.
Consent able patients, willingness and ability to comply with the study procedures.
No spinal cord lesions only LMD disease
Recruitment by radiation oncology faculty in consultation with Dr. De. . .

Exclusion

Age \< 18 years
Pregnant or breastfeeding individuals.
History of cancer.
History of spinal cord lesions including malignant, demyelinating, or inflammatory.
History of prior spinal surgery.
History of implantable devices.
History of MR claustrophobia.
Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
Scoliosis.
Age \< 18 years
History of spinal cord lesions including malignant, demyelinating, or inflammatory.
History of prior spinal surgery.
History of implantable devices.
History of MR claustrophobia.
Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
Scoliosis.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)